Collins, Thomas R.
doi: 10.1097/01.NT.0000520852.35562.83
Features
In a new gene therapy trial, infants with spinal muscular atrophy survived longer without adverse events and achieved developmental milestones. Independent experts said the therapy should be studied and compared with the recently-approved drug, nusinersen.
BOSTON All 15 infants treated with gene therapy for spinal muscular atrophy type 1 (SMA-1) survived past the age at which 75 percent of untreated infants typically die or need at least 16 hours a day of ventilation support, according to results of an open-label phase 1 trial reported here in April at the AAN Annual Meeting.
The event-free survival of the infants to at least 13.6 months shows the promise of the proprietary gene therapy known as AVXS-101, for Avexis, the Illinois-based manufacturer that funded the study.
The drug uses an adeno-associated virus 9 AAV9 to deliver a fully functioning survival motor neuron gene to the patient's cells.
Researchers also found that all nine infants born at least 20 months before the January data cut-off reached the 20-months' time point. All of the patients in the trial are alive, and only one has required 16 or more hours per day of ventilator support at 28.8 months, according to the researchers.
The United States Food and Drug Administration (FDA) granted the drug breakthrough therapy status, which will mean faster review, in July.
Jerry R. Mendell, MD, FAAN, the principal investigator of the current study, said SMA-1 is nearly always fatal for children. Dr. Mendell, who conducted the first gene therapy studies on the treatment and developed the neuromuscular gene therapy program at Nationwide Children's Hospital in Columbus, OH, noted that a 2014 study in Neurology, conducted to establish the natural history against which potential therapies could be measured, found that only 25 percent of children with SMA-1 survive without permanent ventilation beyond 13.5 months. And only 8 percent of untreated infants live beyond 20 months.
In the current study, 12 of the 15 children were given the high dose of the drug. All of these infants have reached at least one milestone, and most have achieved several milestones, such as bringing their hands to their mouths, head control, and sitting. Two children stand and walk independently, and eight can talk.
These are milestones that are essentially never achieved in untreated children, said Dr. Mendell, who reported he has no financial interest in the drug.
None of them ever learn to talk and as they approach their death march, they can no longer feed except by G-tube and they basically live in a vegetative state, he said. And all that has changed dramatically.
Dr. Mendell emphasized the importance of early treatment. The two best patients in our clinical trial were those who were treated very early, and they very rapidly reversed their course; they are now walking, he said. Many of the patients in the trial were treated early because they have a family history [for SMA] and were recognized prenatally. That is what facilitated the study and also what will make a difference in the long run.
He added: I'm hoping the results of this study will allow for newborn-screening for this disease. That will provide a pathway for early treatment.
Last year, the FDA approved the new SMA drug nusinersen, an antisense oligonucleotide therapy, which uses targeted RNA binding to boost production of a protein in which SMA patients are deficient. Dr. Mendell said it's possible that the two drugs could work well together, although this hasn't been evaluated yet.
What we all wonder about on the gene therapy side and on the oligonucleotide side is whether these treatments could be complementary, he said. We'll know the answer to that because some of our patients have requested opportunity to move to nusinersen.
He noted that is an option for patients after their two-year enrollment commitment is reached.
In a review of the abstract, Brent L. Fogel, MD, PhD, FAAN, associate professor of neurology and human genetics at the University of California, Los Angeles, said the results sound promising, and he agreed that the therapy should be compared with nusinersen.
Given the recent success of the FDA-approved antisense oligonucleotide therapies which increase production of SMN protein by altering the splicing of the endogenous SMN2 gene, rather than replacing the damaged SMN1 gene it would be important to compare the risk and benefit between the two approaches to determine the optimal treatment for patients with SMA, who previously had none at all, he said.
He said that other clinical questions remain, as well. It would be of key interest to know what cells the virus is targeting, the resulting gene expression initially and whether that is maintained, and if any side effects are observed as the patients are followed over time, Dr. Fogel said. This would have implications for similar future therapies in other neurogenetic disorders.
Kathryn J. Swoboda, MD, director of the neurogenetics program at the Massachusetts General Hospital for Children, who was a site leader in the multi-center trial on nusinersen, noted that the evidence of gene therapy's efficacy is limited in scope, at least for now.
It's a viral-derived vector, she said, referring to the AAV-9 used in the gene therapy trial. It's a common virus that people are ultimately exposed to so they produce antibodies with time. So the proof that it works is only in babies right now, she said
If you take a young baby with SMA, those are where the phenomenal results are. Even if you took a 9-month-old or an 8-month-old or a 7-month-old with a severe form of disease, it didn't do much, because by then they've already had devastating loss of motor neurons. So we don't know how this would be tolerated in older patients and adults, and we don't have the capacity to make enough virus to deliver it to those patients at this point, and so it's going to take some additional time to do those studies.
The approval of nusinersen could complicate the future of trials on gene therapy, she said.
You've already got an approved drug and how do you design those trials? Do you say they can't get a drug we know might help them? And what if the therapy for gene therapy doesn't work? A back-up plan to start the approved therapy later could mean it might to be too late to respond, she said.
I think there's a lot to think about from an ethical perspective.
News of new therapies for the disease has drawn tremendous demand for SMA treatment from around the world, she said.
We've gotten calls from parents of newborns, prenatal cases, all the way up to 70-year-old patients who want something because it's a progressive disease, she said. And even though it's slowly progressive after a certain point, you're still losing something continuously over time.... They don't even care if it's a major improvement. They just want to stay where they are.
Nonetheless, the path forward is not clear, she said.
Does this cure? Do we have a cure yet? No. We have a really promising set of therapies that are so above anything we've seen for neurodegeneration that it's tremendously exciting. But it doesn't mean that it makes it easy to figure out how to do this.
. AAN Annual Meeting Abstract CT.003: Mendell J, Al-Zaidy SA, Shell R, et al. AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: Event free survival and achievement of developmental milestones. http://bit.ly/genetherapy-abstract.
. AAN Annual Meeting Abstract CCI.002: Kuntz N, Farwell W, Zhong ZJ, et al, on behalf of the ENDEAR Study Group. Nusinersen in infants diagnosed with spinal muscular atrophy (SMA): Study design and initial interim efficacy and safety findings from the phase 3 international ENDEAR study. http://bit.ly/nusinersen-abstract
. Sign up for the video link to the plenary here: http://aan.informz.net/AAN/pages/17_AMOD_Form.
View post:
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]